Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP2
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
CP2 is a neuroprotective small molecule that targets mitochondria. It has demonstrated the ability to rescue mitochondrial dysfunction and associated Alzheimer's Disease (AD)-like transcriptomic changes in preclinical models. Specifically, CP2 treatment has been shown to augment mitochondrial biogenesis, mitochondrial turnover, synaptic activity, autophagy, and redox balance, while also reducing inflammation. Its mechanism involves mediating neuroprotective effects even in the presence of reduced mitochondrial complex I (mtCI) activity, highlighting the critical role of mitochondrial function in AD development and treatment.
- Other names
- Tricyclic pyrone CP2MCI-inhibitor CP2
02
Targets
ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on CP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP2.